UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Journal of the American Heart Association, 2020-07, Vol.9 (13), p.e017559

2020

Volltextzugriff (PDF)

Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience

Journal of thrombosis and haemostasis, 2020-06, Vol.18 (6), p.1320-1323

2020

Volltextzugriff (PDF)

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.628-636

2016

Volltextzugriff (PDF)

Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2018-09, Vol.16 (9), p.1891-1894

2018

Volltextzugriff (PDF)

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Journal of clinical pharmacology, 2016-05, Vol.56 (5), p.637-645

2016

Volltextzugriff (PDF)

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.2119-2126

2015

Volltextzugriff (PDF)

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

Journal of thrombosis and haemostasis, 2019-10, Vol.17 (10), p.1772-1778

2019

Volltextzugriff (PDF)

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

Journal of thrombosis and haemostasis, 2015-12, Vol.13 (12), p.2187-2191

2015

Volltextzugriff (PDF)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Journal of the American Heart Association, 2016-06, Vol.5 (6), p.n/a

2016

Volltextzugriff (PDF)

Bleeding incidence and risk factors among cancer patients treated with anticoagulation

American journal of hematology, 2019-07, Vol.94 (7), p.780-785

2019

Volltextzugriff (PDF)

Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages

Journal of thrombosis and haemostasis, 2020-07, Vol.18 (7), p.1637-1647

2020

Volltextzugriff (PDF)

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis

Pharmacotherapy, 2024-05, Vol.44 (5), p.394-408

2024

Volltextzugriff (PDF)

Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials

Journal of thrombosis and haemostasis, 2015-11, Vol.13 (11), p.2012-2020

2015

Volltextzugriff (PDF)

Full-dose rivaroxaban in patients with a history of bariatric surgery: bridging the knowledge gap through a phase 1 study

Journal of thrombosis and haemostasis, 2024-10, Vol.22 (10), p.2844-2854

2024

Volltextzugriff (PDF)

Direct Comparison of the Effectiveness and Safety Among Direct Oral Anticoagulants and Warfarin in Japanese Patients: Nationwide Cohort Study in Japan

Clinical pharmacology and therapeutics, 2024-10, Vol.116 (4), p.1023-1033

2024

Volltextzugriff (PDF)

Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single‐Dose Study

Clinical pharmacology and therapeutics, 2024-09, Vol.116 (3), p.736-746

2024

Volltextzugriff (PDF)

Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer‐associated venous thromboembolism

American journal of hematology, 2019-11, Vol.94 (11), p.1185-1192

2019

Volltextzugriff (PDF)

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures

Pharmacotherapy, 2022-10, Vol.42 (10), p.780-791

2022

Volltextzugriff (PDF)

Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial

Alimentary pharmacology & therapeutics, 2024-09, Vol.60 (6), p.737-748

2024

Volltextzugriff (PDF)

Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial

Clinical cardiology (Mahwah, N.J.), 2019-05, Vol.42 (5), p.568-571

2019

Volltextzugriff (PDF)

Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study

Journal of thrombosis and haemostasis, 2017-10, Vol.15 (10), p.2017-2028

2017

Volltextzugriff (PDF)

Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial

Journal of thrombosis and haemostasis, 2024-06, Vol.22 (6), p.1704-1714

2024

Volltextzugriff (PDF)

Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents

British journal of haematology, 2020-08, Vol.190 (4), p.555-561

2020

Volltextzugriff (PDF)

Evaluating the safety and effectiveness of direct oral anticoagulants compared with warfarin in very elderly patients with atrial fibrillation with and without low bodyweight

Journal of thrombosis and haemostasis, 2024-11, Vol.22 (11), p.3107-3124

2024

Volltextzugriff (PDF)

The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy

British journal of haematology, 2024-08, Vol.205 (2), p.473-477

2024

Volltextzugriff (PDF)

1 – 25 von 295

Suche als RSS-Feed

Aktive Filter

KollektionWiley Online Library

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(294)
Mit Volltextzugriff
(274)

Publikationsform

Artikel
(295)

Sprache

Englisch
(295)

Erscheinungsjahr

n.n

Thema

Humans
(290)
Life Sciences & Biomedicine
(285)
Science & Technology
(285)
Factor Xa Inhibitors - Adverse Effects
(158)
Male
(153)
Anticoagulants - Adverse Effects
(145)
Female
(142)
Cardiovascular System & Cardiology
(121)
Middle Aged
(116)
Aged
(115)
Hemorrhage - Chemically Induced
(113)
Factor Xa Inhibitors
(109)
Anticoagulants
(107)
Administration, Oral
(98)
Hematology
(95)
Pharmacology & Pharmacy
(95)
Factor Xa Inhibitors - Administration & Dosage
(88)
Treatment Outcome
(88)
Anticoagulants - Administration & Dosage
(86)
Anticoagulants - Therapeutic Use
(74)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(4)

Menü

Weitere Dienste

Einstellungen

Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges

Direct oral anticoagulant plasma levels’ striking increase in severe COVID‐19 respiratory syndrome patients treated with antiviral agents: The Cremona experience

Pharmacokinetics, pharmacodynamics, and safety of apixaban in subjects with end-stage renal disease on hemodialysis

Role of direct oral anticoagulants in the treatment of cancer‐associated venous thromboembolism: guidance from the SSC of the ISTH

Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban

Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH

The use of direct oral anticoagulants for primary thromboprophylaxis in ambulatory cancer patients: Guidance from the SSC of the ISTH

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation

Bleeding incidence and risk factors among cancer patients treated with anticoagulation

Evaluation of andexanet alfa and four‐factor prothrombin complex concentrate (4F‐PCC) for reversal of rivaroxaban‐ and apixaban‐associated intracranial hemorrhages

Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta‐analysis

Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta‐analysis of randomized controlled trials

Full-dose rivaroxaban in patients with a history of bariatric surgery: bridging the knowledge gap through a phase 1 study

Direct Comparison of the Effectiveness and Safety Among Direct Oral Anticoagulants and Warfarin in Japanese Patients: Nationwide Cohort Study in Japan

Pharmacokinetics, Pharmacodynamics, and Safety of Edoxaban in Pediatric Subjects: A Phase I Single‐Dose Study

Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer‐associated venous thromboembolism

Reversal of apixaban and rivaroxaban with andexanet alfa prior to invasive or surgical procedures

Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low‐dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial

Efficacy and safety of apixaban vs warfarin in patients with atrial fibrillation and prior bioprosthetic valve replacement or valve repair: Insights from the ARISTOTLE trial

Dissociation between the pharmacokinetics and pharmacodynamics of once‐daily rivaroxaban and twice‐daily apixaban: a randomized crossover study

Extending venous thromboembolism secondary prevention with apixaban in cancer patients. The EVE trial

Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents

Evaluating the safety and effectiveness of direct oral anticoagulants compared with warfarin in very elderly patients with atrial fibrillation with and without low bodyweight

The comparative efficacy and safety of factor Xa inhibitors and warfarin for primary thromboprophylaxis in multiple myeloma patients undergoing immunomodulatory therapy

Aktive Filter

Suchergebnisse filtern